Poly ICLC inhibits Plasmodium cynomolgi B malaria infection in rhesus monkeys

Journal of Interferon and Cytokine Research

Volumn 16, Issue 1, 1996, Pages 49-52

  Puri, Sunil K ^a   Dutta, Guru P ^a   Levy, Hilton B ^b   Maheshwari, Radha K ^c  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL RESPONSE MODIFIER; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CD4 ANTIGEN; CD8 ANTIGEN; INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SMEAR; CONTROLLED STUDY; FEMALE; IMMUNOSTIMULATION; INOCULATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALARIA; MALE; NONHUMAN; PARASITEMIA; PLASMODIUM CYNOMOLGI; PRIORITY JOURNAL; PROPHYLAXIS; RHESUS MONKEY; SCHIZONT; SPOROZOITE; TROPHOZOITE;

ANIMALIA; MACACA MULATTA; PLASMODIUM CYNOMOLGI;

EID: 0030052548     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1996.16.49     Document Type: Article

References (33)

1. JAHIEL, R.I., NUSSENZWEIG, R.S., VANDERBERG, J., and VILCEK, J. (1968). Antimalarial effect of interferon inducers at different stages of development of Plasmodium berghei in the mouse. Nature (Lond.) 220, 710-711.
2. JAHIEL, R.I., NUSSENZWEIG, R.S., VILCEK, J., and VANDERBERG, J. (1969). Protective effect of interferon inducers on Plasmodium berghei malaria. Am. J. Trop. Med. Hyg. 18, 823-835.
3. JAHIEL, R.I., VILCEK, J., and NUSSENZWEIG, R.S. (1970). Exogenous interferon protects mice against Plasmodium berghei malaria. Nature (Lond.) 227, 1350-1351.
4. JAHIEL, R.I., VILCEK, J., NUSSENZWEIG, R.S., and VANDERBERG, J. (1968). Interferon inducers protect mice against Plasmodium berghei. Science 161, 802-804.
5. SCHULTZ, W.W., HUANG, K., and GORDON, F.B. (1968). Role of interferon in experimental mouse malaria. Nature (Lond.) 220, 709-710.
6. MAHESHWARI, R.K., CZARNIECKI, C.W., DUTTA, G.P., PURI, S.K., DHAWAN, B.N., and FRIEDMAN, R.M. (1986). Recombinant human gamma interferon inhibits simian malaria. Infect. Immun. 53, 628-630.
7. MAHESHWARI, R.K. (1990). Role of cytokines in malaria infection. Bull. World. Health Organ. 68, 138-144.
8. FERREIRA, A., SCHOFIELD, L., ENEA, V., SCHELLEKENS, H., DE DERMEI, P.V., COLLINS, W.E., NUSSENZWEIG, R.S., and NUSSENZWEIG, V. (1986). Inhibition of development of exoerythrocytic forms of malaria parasites by gamma interferon. Science 232, 881-884.
9. MELLOUK, S., MAHESHWARI, R.K., RHODES-FEUILLETTE, A., BEAUDOIN, R.L., BERBIGUIER, N., MATILE, H., MILTGEN, F., LANDAU, I., PIED, S., CHIGOT, J.P., FRIEDMAN, R.M., and MAZIER, D. (1987). Inhibitory activity of interferons and interleukin 1 on the development of Plasmodium falciparum in human hepatocyte cultures. J. Immunol. 139, 4192-4195.
10. LEVY, H.B., BEAR, G., BARON, S., BUCKLER, C.E., GIBBS, C.J., IADAROLA, M.J., LONDON, W.T., and RICE, J. (1975). A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J. Infect. Dis. 132, 434-439.
11. BEVER, C.T., MCFARLAND, H.F., MCFARLIN, D.E., and LEVY, H.B. (1988). The kinetics of interferon induction by Poly ICLC in humans. J. Interferon Res. 8, 419-425.
12. LEVY, H.B., LYOVSKY, E., RILEY, F., HARRINGTON, D., ANDERSON, A., MOE, J., HILFENHAUS, J., and STEPHEN, E. (1980). Immune modulating effects of Poly ICLC. Ann. NY Acad. Sci. 350, 33-41.
13. SHORTT, H.E. (1951). History of recent researchers in tissue phases of the malaria parasite at London School of Hygiene and Tropical Medicine. Trans. R. Soc. Trop. Med. Hyg. 45, 75-188.
14. SHORTT, H.E., and GARNHAM, P.C.C. (1948). The preerythrocytic development of Plasmodium cynomolgi and Plasmodium vivax. Trans. R. Soc. Trop. Med. Hyg. 41, 785-795.
15. LEVY, H.B., RILEY, F.L., LVOVSKY, E., and STEPHEN, E.E. (1981). Interferon induction in primates by stabilized polyribosinic acid-polyribocytidylic acid: effect of component size. Infect. Immun. 34, 416-421.
16. TARLOV, A.R., BREWER, G.J., CARSON, P.E., and ALVING, A.A. (1962). Primaquine sensitivity. Arch. Intern. Med. 109, 209-234.
17. LEVY, H.B. (1987). Clinical studies with polynucleotides. In: The Interferon System, A Current Review to 1987. S. Baron, F. Dianzani, G.J. Stanton, and W.R. Fleishmann (eds.) Austin: University of Texas Press, pp. 469-475.
18. HARRINGTON, D.G., CRABES, C.L., HILMAS, D.E., BROWN, J.R., HIGHBEE, G.A., COLE, F.E., JR., and LEVY, H.B. (1979). Adjuvant effects of low doses of a nuclease-resistant derivative of polyinosinic acid-polycytidylic acid on antibody responses of monkeys to inactivated Venezuelan equine encephalomyelitis virus vaccine. Infect. Immun. 24, 160-166.
19. RETTENMAIER, M.A., BERMAN, M.L., and DISAIA, P.J. (1986). Treatment of advanced ovarian cancer with Poly-ICLC. Gynecol Oncol. 24, 359-361.
20. KROWN, S.E., KERR, D., STEWART, W.E., FIELD, A.K., and OETTGEN, H.F. (1985). Phase I trials of Poly ICLC in advanced cancer. J. Biol. Response Mod. 4, 640-649.
21. THERIAULT, R.L., HORTOBAGYE, G.N., BUDZAR, A.U., LEVY, H.B., and HERSH, E.M. (1986). Evaluation of Poly ICLC in metastatic breast cancer. Cancer Treat. Rep. 70, 1341-1342.
22. DROLLER, M.J. (1987). Immunotherapy of metastatic renal cell carcinoma with polyinosinic-polycytidylic acid. J. Urol. 137, 202-206.
23. HAWKINS, M.J., LEVIN, M., and BORDEN, E.C. (1985). An ECOG phase I-II pilot study of Poly ICLC in patients with metastatic malignant melanoma. J. Biol. Response Mod. 4, 664-668.
24. NAKAMURA, O., SHITARA, N., MATSUTANI, M., TAKAKURA, K., and MACHIDA, H. (1982). Phase I-II trials of Poly-ICLC in malignant brain tumor patients. J. Interferon Res. 2, 1-4.
25. LEVY, H., and SALAZAR, A.M. (1992). Interferon inducers. In: Interferon: Principles and Medical Applications. S. Baron, D.H. Copenhaver, and F. Dianzani (eds.) Galveston: University of Texas Medical Branch, pp. 65-76.
26. SALAZAR, A.M., MORALES, J.O., LEVY, H.B., DE JESUS, C., SARIN, P., HAWKES, C., and MARTIN, A. (1990). Intramuscular Poly-ICLC in HIV infection: preliminary findings. Neurology 40(Suppl. 1), 238.
27. TALMADGE, J.E., and HARTMAN, D. (1985). Optimization of an immunotherapeutic protocol with Poly-ICLC. J. Biol. Response Mod. 4, 484-489.
28. TALMADGE, J.E., HERBERMAN, R.B., CHIRIGOS, M.A., MALUISH, A.E., SCHNEIDER, M.A., ADAMS, J.S., PHILIPS, H., THURMAN, G.B., VARESIO, L., LONG, C., OLDHAM, R.K., and WILTROUT, R.H. (1985). Hyporesponsiveness to augmentation of murine natural killer cell activity in different anatomical compartments by multiple injections of various immunomodulators, including recombinant interferons and interleukin 2. J. Immunol. 135, 2483-2491.
29. SALAZAR, A.M., ENGEL, W.K., and LEVY, H.B. (1981). Poly ICLC in the treatment of postinfectious demyelinating encephalomyelitis. Arch. Neurol. 38, 382-383.
30. BEVER, C., SALAZAR, A.M., NEELEY, E., FERRARACIO, B., MCFARLAND, H., and MCFARLIN, D. (1986). Preliminary trial of Poly-ICLC in chronic progressive multiple sclerosis. Neurology 36, 489-493.
31. NUSSLER, A.K., RENIA, L., PASQUETTO, V., MILTOGEN, F., MATILE, H., and MAZIER, D. (1993). In vivo induction of the nitric oxide pathway in hepatocytes after injection with irradiated malaria sporozoites, malaria blood parasites or ajuvants. Eur. J. Immunol. 23, 882-887.
32. GREEN, S.J., MELLOUK, S., HOFFMAN, S.L., MELTZER, M.S., and NACY, C.A. (1990). Cellular mechanisms of non-specific immunity to intracellular infection: cytokine-induced synthesis of toxic nitrogen oxides from L-arginine by macrophages and hepatocytes. Immunol. Lett. 25, 15-20.
33. + T cells. J. Exp. Med. 180, 353-358.